Completed
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
H9H-MC-JBAK - ClinicalTrials.gov - NCT01246986
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
How long will I be in the trial?
none
Completed
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
H9H-MC-JBAK - ClinicalTrials.gov - NCT01246986
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
How long will I be in the trial?
none
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
none
Participants must NOT
Trial Summary
Conditions the trial is for
Liver Cancer
What the trial is testing?
LY2157299, Sorafenib, Ramucirumab
Could I receive a Placebo?
no
Enrollment Goal
235
Trial Dates
March 2011 - December 2019
Trial Phase
2
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
none
Participants must NOT
Trial Summary
Conditions the trial is for
Liver Cancer
What the trial is testing?
LY2157299, Sorafenib, Ramucirumab
Could I receive a Placebo?
no
Enrollment Goal
235
Trial Dates
March 2011 - December 2019
Trial Phase
2
Not the right fit? Sign up to receive updates on new Liver Cancer trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Liver Cancer Resources
